 The FDA has granted Fast Track designation to Akari Therapeutics Plcs NASDAQ: AKTX nomacopan to treat patients with moderate and severe Bullous Pemphigoid BP. Nomacopan has also been granted orphan drug designation for nomacopan to treat BP by the FDA and the European Medicines Agency EMA. 